Author

N. Garnier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Attarbaschi· 1 shared A. Beishuizen· 1 shared A. Broisat· 1 shared A. Zarubica· 1 shared B. Burkhardt· 1 shared B. Serrano· 1 shared C. D. Baldus· 1 shared C. Gotorbe· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Attarbaschi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

E. Kroeze, I. Iaccarino, M. M. Kleisman, M. Mondal, T. Beder, M. Khouja, M. P. Hoeppner, M. Scheijde-Vermeulen, L. A. Kester, M. Brueggemann, C. D. Baldus, G. Cario, R. S. Bladergroen, N. Garnier, A. Attarbaschi, , W. Klapper

This study presents the first comprehensive mutational and transcriptional analysis of B-cell precursor lymphoblastic lymphoma (BCP-LBL), revealing molecular similarities to BCP-ALL but with distinct mutation patterns in epigenetic modifiers.

bioRxiv · Dec 27, 2023Cancer Biology

nanoCLAMP potently neutralizes SARS-CoV-2 and protects K18-hACE2 mice from infection

Q. Pagneux, N. Garnier, M. Fabregue, S. Sharkaoui, S. Mazzoli, I. Engelmann, R. Boukherroub, M. Strecker, E. Cruz, P. Ducos, A. Zarubica, R. Suderman, S. Szunerits

This paper develops a multi-epitope nanoCLAMP that neutralizes SARS-CoV-2 variants and protects mice from infection.

bioRxiv · Apr 3, 2023 · PreprintBioengineering

Integrin-alpha V beta 3 is a fundamental factor in medulloblastoma tumorigenicity and radioresistance: A new game for an old player

W. Echavidre, J. Durivault, C. Gotorbe, T. Blanchard, M. Pagnuzzi, V. Vial, F. Raes, A. Broisat, R. Villeneuve, R. Amblard, N. Garnier, C. Ortholan, M. Faraggi, B. Serrano, V. Picco, C. Montemagno

This study investigates the role of integrin-v{beta}3 in medulloblastoma tumorigenicity and radioresistance, showing its correlation with radioresistance and response to cilengitide.

bioRxiv · Mar 8, 2023 · PreprintCancer Biology